T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1301
DELISTED
Aerie Pharmaceuticals
AERI
| $10.8M | ﹤0.01% |
365,043
+25
| +0% | +$963 |
|
1302
Harley-Davidson
HOG
$2.9B
| $10.7M | ﹤0.01% |
299,698
+418
| +0.1% | +$15.2K |
|
1303
Markel Group
MKL
$22.8B
| $10.6M | ﹤0.01% |
9,766
-37
| -0.4% | -$38.8K |
|
|
SFE
1304
DELISTED
Safeguard Scientifics, Inc.
SFE
| $10.6M | ﹤0.01% |
877,741
-265,534
| -23% | -$3.11M |
|
1305
ePlus
PLUS
$2.31B
| $10.5M | ﹤0.01% |
305,394
-2,210
| -0.7% | -$91.8K |
|
|
MGP
1306
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $10.5M | ﹤0.01% |
342,443
-980,598
| -74% | -$31.1M |
|
|
PHX
1307
DELISTED
PHX Minerals
PHX
| $10.5M | ﹤0.01% |
801,827
+403
| +0.1% | +$5.77K |
|
|
PHAS
1308
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $10.4M | ﹤0.01% |
796,236
+144,535
| +22% | +$1.77M |
|
1309
Ichor Holdings
ICHR
$2.67B
| $10.3M | ﹤0.01% |
434,829
+304
| +0.1% | +$7.1K |
|
1310
Galicia Financial Group
GGAL
$7.23B
| $10.2M | ﹤0.01% |
288,086
-457,570
| -61% | -$12.3M |
|
1311
Royal Gold
RGLD
$19.1B
| $10.2M | ﹤0.01% |
99,765
+61,919
| +164% | +$5.58M |
|
1312
Etsy
ETSY
$7.4B
| $10.2M | ﹤0.01% |
165,961
-1,362,960
| -89% | -$89M |
|
1313
Helmerich & Payne
HP
$4.3B
| $10.1M | ﹤0.01% |
200,420
+7,116
| +4% | +$392K |
|
1314
Nu Skin
NUS
$236M
| $10M | ﹤0.01% |
203,705
-50
| -0% | -$2.54K |
|
1315
Denali Therapeutics
DNLI
$3.97B
| $9.99M | ﹤0.01% |
481,140
-202
| -0% | -$4.53K |
|
|
MYOV
1316
DELISTED
Myovant Sciences Ltd.
MYOV
| $9.84M | ﹤0.01% |
1,086,893
+274,745
| +34% | +$4.1M |
|
1317
Wayfair
W
$13.9B
| $9.49M | ﹤0.01% |
65,003
-1,723
| -3% | -$259K |
|
1318
Capri Holdings
CPRI
$1.77B
| $9.48M | ﹤0.01% |
273,499
-1,996
| -0.7% | -$81.2K |
|
1319
eHealth
EHTH
$38.8M
| $9.43M | ﹤0.01% |
109,489
+34,652
| +46% | +$2.33M |
|
1320
Williams-Sonoma
WSM
$28.5B
| $9.36M | ﹤0.01% |
288,086
-10,006
| -3% | -$287K |
|
1321
OGE Energy
OGE
$9.71B
| $9.31M | ﹤0.01% |
218,838
+5,252
| +2% | +$222K |
|
1322
Inogen
INGN
$154M
| $9.29M | ﹤0.01% |
139,147
-52,558
| -27% | -$4M |
|
1323
White Mountains Insurance
WTM
$5.11B
| $9.16M | ﹤0.01% |
8,972
+1
| +0% | +$962 |
|
1324
Affiliated Managers Group
AMG
$9.7B
| $9.12M | ﹤0.01% |
98,992
+89
| +0.1% | +$8.73K |
|
|
FL
1325
DELISTED
Foot Locker
FL
| $9.1M | ﹤0.01% |
216,988
-1,005
| -0.5% | -$52.3K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.